TOP STORIES

• BUSINESS First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
  August 30, 2023

• ORGANIZATION JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
  August 29, 2023

• REGULATORY Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
  August 29, 2023

• REGULATORY Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
  August 28, 2023

• REGULATORY MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
  August 25, 2023

• ACADEMIA Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
  August 25, 2023

• REGULATORY Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
  August 24, 2023

• REGULATORY Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
  August 24, 2023

• REGULATORY Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
  August 24, 2023

• REGULATORY Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
  August 24, 2023

• REGULATORY Japan Approves Enhertu’s NSCLC Use, More Label Expansions
  August 24, 2023

• REGULATORY Japan Looks to Launch Innovation Tax Incentive to Ramp Up R&D Investments
  August 23, 2023

• REGULATORY Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
  August 23, 2023

• REGULATORY Eisai’s Alzheimer’s Drug Clears Advisory Panel, Now in Line for Japan Approval
  August 22, 2023

• REGULATORY MOF Budget Examiner Eager to Reshuffle Resources for Patented Drugs, LLPs
  August 21, 2023

• BUSINESS Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
  August 18, 2023

• BUSINESS Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
  August 17, 2023

• REGULATORY Japan OKs 1st DPP-4 Generic for Januvia, Zytiga Draws 6 Entrants towards December Listing
  August 16, 2023

• BUSINESS Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
  August 14, 2023

• REGULATORY Entries into Generic Business Should Be Regulated by Law: LDP Lawmaker
  August 10, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• 63
• …
• Next ›
• 最終 »